Nitazoxanide
Nitazoxanide, sold under the brand name Alinia among others, is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections. It is indicated for the treatment of infection by Cryptosporidium parvum and Giardia lamblia in immunocompetent individuals and has been repurposed for the treatment of influenza. Nitazoxanide has also been shown to have in vitro antiparasitic activity and clinical treatment efficacy for infections caused by other protozoa and helminths; evidence as of 2014 suggested that it possesses efficacy in treating a number of viral infections as well.
Clinical data | |
---|---|
Trade names | Alinia, Nizonide, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603017 |
License data |
|
Routes of administration | By mouth |
Drug class | Antiprotozoal Broad-spectrum antiparasitic Broad-spectrum antiviral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | Nitazoxanide: ? Tizoxanide: over 99% |
Metabolism | Rapidly hydrolyzed to tizoxanide |
Metabolites | tizoxanide tizoxanide glucuronide |
Elimination half-life | 3.5 hours |
Excretion | Kidney, bile duct, and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.054.465 |
Chemical and physical data | |
Formula | C12H9N3O5S |
Molar mass | 307.28 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Chemically, nitazoxanide is the prototype member of the thiazolides, a class of drugs which are synthetic nitrothiazolyl-salicylamide derivatives with antiparasitic and antiviral activity. Tizoxanide, an active metabolite of nitazoxanide in humans, is also an antiparasitic drug of the thiazolide class.
Nitazoxanide tablets were approved as a generic medication in the United States in 2020.